Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 176 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neutrophils Clear all
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 13, 2026, 6:33 AM EDT
Completed Phase 4 Interventional Results available

Kidney Damage in Patients With Normal eGFR

NCT01137786
View directory record Official record
Conditions
Coronary Artery Stenosis
Interventions
Non ionic contrast media comparator
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Springfield, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced Sep 13, 2026, 6:33 AM EDT
Active, not recruiting Phase 1 Interventional

CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101

NCT06152172
View directory record Official record
Conditions
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
Interventions
KYV-101, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
David Porter
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 13, 2026, 6:33 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290
View directory record Official record
Conditions
ANCA Associated Vasculitis (AAV)
Interventions
Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 13, 2026, 6:33 AM EDT
Terminated Not applicable Interventional Results available

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

NCT03906227
View directory record Official record
Conditions
ANCA Associated Vasculitis
Interventions
ENUMERATION OF CD5+ B Cells
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 13, 2026, 6:33 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 13, 2026, 6:33 AM EDT
Completed Phase 2 Interventional

Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes

NCT00004567
View directory record Official record
Conditions
Vasculitis, Wegener's Granulomatosis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 13, 2026, 6:33 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

LCI Apheresis to Obtain Plasma or White Blood Cells

NCT00562601
View directory record Official record
Conditions
Apheresis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
864 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1988 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 13, 2026, 6:33 AM EDT
Terminated No phase listed Observational

Apheresis to Obtain Plasma or White Blood Cells for Laboratory Studies

NCT00001349
View directory record Official record
Conditions
Leukopheresis, Plasmapheresis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 13, 2026, 6:33 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines

NCT02563678
View directory record Official record
Conditions
Infection
Interventions
Hyperbaric Oxygen, Hyperbaric Air/Oxygen, Normobaric oxygen
Drug · Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 13, 2026, 6:33 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses

NCT06128915
View directory record Official record
Conditions
Aging
Interventions
vaccine
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 13, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Validation of a Low-cost Platelet-Rich Plasma (PRP)

NCT06184048
View directory record Official record
Conditions
Platelet-Rich Plasma (PRP), Knee Osteoarthritis (OA)
Interventions
Intra-Articular knee injection of LC-PRP
Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 13, 2026, 6:33 AM EDT
Completed No phase listed Observational

Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders

NCT00433862
View directory record Official record
Conditions
Polycythemia Vera, Essential Thrombocytosis, Idiopathic Myelofibrosis, Neutrophils, Chronic Myeloproliferative Disorders
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 13, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Spectra Optia PMN Cell Collection Procedure

NCT01805180
View directory record Official record
Conditions
Granulocyte/ Polymorphonuclear Cells
Interventions
Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System), Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)
Device
Lead sponsor
Terumo BCT
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
3
States / cities
Denver, Colorado • Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 13, 2026, 6:33 AM EDT
Active, not recruiting No phase listed Observational

Neutrophil Phenotypic Profiling and Surgical Site Infections in Surgical Patients

NCT04773457
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Surgical Site Infection
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
12 Months to 19 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 13, 2026, 6:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Range of Neutrophil Response to 20,000 EU of Clinical Center Reference Endotoxin in Otherwise Healthy Smokers

NCT00753870
View directory record Official record
Conditions
Healthy Smokers
Interventions
CCRE inhalation
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2011 · Synced Sep 13, 2026, 6:33 AM EDT
Completed No phase listed Observational Results available

An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis

NCT01613599
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions
Rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 13, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies

NCT00072592
View directory record Official record
Conditions
Wegener's Granulomatosis
Interventions
Rituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 13, 2026, 6:33 AM EDT
Completed No phase listed Observational

Evaluation of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Early and Evolving Acute Kidney Injury

NCT00445809
View directory record Official record
Conditions
Kidney Failure, Acute
Interventions
Not listed
Lead sponsor
Abbott RDx Cardiometabolic
Other
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Denver, Colorado • Washington D.C., District of Columbia • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2009 · Synced Sep 13, 2026, 6:33 AM EDT
Terminated Not applicable Interventional

Use of Biomarkers to Optimize Fluid Dosing,CRRT Initiation and Discontinuation in Pediatric ICU Patients With AKI

NCT01416298
View directory record Official record
Conditions
Acute Kidney Injury, Fluid Overload
Interventions
Continuous Renal Replacement Therapy
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 25 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Sep 13, 2026, 6:33 AM EDT
Recruiting Phase 2Phase 3 Interventional

TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With Polyangiitis

NCT07176546
View directory record Official record
Conditions
Granulomatosis With Polyangiitis, Wegener's, GPA
Interventions
Avacopan, Placebo
Drug
Lead sponsor
Robert Spiera, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Edison, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 13, 2026, 6:33 AM EDT
Completed Early Phase 1 Interventional

Stress, Inflammation and Immune Response Pilot Study- Aim 3

NCT04857151
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Inflammation
Interventions
App based mindfulness program (ABMP)
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 13, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Linezolid on Ex Vivo Neutrophil and Monocyte Function in Healthy Males

NCT01544673
View directory record Official record
Conditions
Gram Positive Infection
Interventions
linezolid, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 13, 2026, 6:33 AM EDT
Completed No phase listed Observational

Reproductive Health in Men and Women With Vasculitis

NCT02176070
View directory record Official record
Conditions
Giant Cell Arteritis, Takayasu's Arteritis, Polyarteritis Nodosa, Wegener's Granulomatosis, Microscopic Polyangiitis, Churg-Strauss Syndrome, Behcet's Disease, Kawasaki Disease, Henoch-schoenlein Purpura, Vasculitis, Central Nervous System, Drug-induced Necrotizing Vasculitis
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 13, 2026, 6:33 AM EDT